Clinical and experimental studies on stomach carcinoma treated with Yangwei Kangliu granules

Table 1 Change of red blood cell immune function in the Yangwei Kangliu treatment group (%, ^-x ± s)

	n	C-3b-RR	Immune complex	Tumor and red cell
Normal	30	17.3 ± 5.04	9.6 ± 1.72	40.6 ± 6.17
Pre-treatment	50	8.8 ± 2.37	13.2 ± 2.88	29.1 ± 6.32
Post-treatment	50	15.0 ± 2.71b	8.9 ± 1.87b	39.2 ± 1.96b

^bP < 0.01 vs pre-treatment.

Table 2 Change in T lymphocyte subset between the Yangwei Kangliu + chemotherapy (treatment) and chemotherapy only (control) group

Group	n	CD3	CD4	CD8	CD4/CD8
Treatment group
Pre-treatment	50	66.00 ± 6.81	38.00 ± 4.52	32.36 ± 2.91	11.23 ± 0.166
Post-treatment	50	66.27 ± 5.55	39.00 ± 4.15	26.45 ± 2.84b	1.48 ± 0.156b
Control group
Pre-treatment	20	63.59 ± 8.32	38.18 ± 6.7	31.56 ± 2.82	1.26 ± 0.22
Post-treatment	20	62.18 ± 9.03	36.37 ± 3.39	32.47 ± 4.89d	1.21 ± 0.2d

^bP < 0.01, Compared with the treatment group in pre-treatment;

^dP < 0.01, Compared with the treatment group in post-treatment.

Table 3 Dynamic changes in tumor weight between experimental groups

Group	n	Day 9 post-inoculation	Day 13 post-inoculation
Control	10	1.27 ± 0.47	2.07 ± 0.42
TCM	10	0.74 ± 0.43ab	2.04 ± 0.21
Chemotherapy	10	1.196 ± 0.23	1.98 ± 0.35

^aP < 0.05, Compared with chemotherapy;

^bP < 0.01, Compared with the control.

Table 4 Dynamic changes in red blood cell-c-3b-receptor and red blood cell-immune complex

Group	Red blood cell-c-3b-receptor			Red blood cell-immune complex
	D3	D9	D13	D3	D9	D13
Control	5.27 ± 2.96	3.57 ± 1.04	2.88 ± 1.10	7.14 ± 1.93	9.80 ± 2.55	12.29 ± 4.83
TCM	13.40 ± 5.70av	7.20 ± 1.27ac	4.37 ± 1.12	3.96 ± 1.51ac	6.45 ± 1.03ac	11.52 ± 2.81
Chemotherapy	3.53 ± 1.17	2.94 ± 1.18	3.15 ± 1.16	7.89 ± 2.76	9.05 ± 2.85	14.30 ± 5.09

^aP < 0.05, Compared with the control;

^cP < 0.05, Compared with chemotherapy; D: Day.